« BackNanomedicine: Nanotechnology, Biology and Medicine
Article in Press

Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer

  • Daniele Vergara, PhD

      Affiliations

    • Laboratory of General Physiology, Department of Biological and Environmental Sciences and Technologies, University of Salento, Lecce, Italy
    • Laboratory of Clinical Proteomic, “Giovanni Paolo II” Hospital, Lecce, Italy
    • ,
  • Claudia Bellomo, MS

      Affiliations

    • NNL–Istituto Nanoscienze, Italy
    • ,
  • Xingcai Zhang, MS

      Affiliations

    • Institute for Micromanufacturing, Louisiana Tech University, Ruston, Louisiana, USA
    • ,
  • Viviana Vergaro, MS

      Affiliations

    • NNL–Istituto Nanoscienze, Italy
    • ,
  • Andrea Tinelli, MD

      Affiliations

    • Department of Obstetrics and Gynaecology, Vito Fazzi Hospital, Lecce, Italy
    • ,
  • Vito Lorusso, MD

      Affiliations

    • Department of Medical Oncology, Vito Fazzi Hospital, Lecce, Italy
    • ,
  • Ross Rinaldi, PhD

      Affiliations

    • NNL-Istituto Nanoscienze, CNR University of Salento, Department of Innovation Engineering, Lecce, Italy
    • ,
  • Yuri M. Lvov, PhD

      Affiliations

    • Institute for Micromanufacturing, Louisiana Tech University, Ruston, Louisiana, USA
    • ,
  • Stefano Leporatti, PhD

      Affiliations

    • NNL–Istituto Nanoscienze, Italy
    • Corresponding Author InformationCorresponding author. NNL, Istituto Nanoscienze, CNR Via Arnesano 16Lecce 73100, Italy.
    • ,
  • Michele Maffia, PhD

      Affiliations

    • Laboratory of General Physiology, Department of Biological and Environmental Sciences and Technologies, University of Salento, Lecce, Italy
    • Laboratory of Clinical Proteomic, “Giovanni Paolo II” Hospital, Lecce, Italy

Received 20 May 2011; accepted 30 October 2011. published online 17 November 2011.
Corrected Proof

Abstract 

The sonication-assisted layer-by-layer (SLBL) technology was developed to combine necessary factors for an efficient drug-delivery system: (i) control of nanocolloid size within 100 – 300 nm, (ii) high drug content (70% wt), (iii) shell biocompatibility and biodegradability, (iv) sustained controlled release, and (v) multidrug-loaded system. Stable nanocolloids of Paclitaxel (PTX) and lapatinib were prepared by the SLBL method. In a multidrug-resistant (MDR) ovarian cancer cell line, OVCAR-3, lapatinib/PTX nanocolloids mediated an enhanced cell growth inhibition in comparison with the PTX-only treatment. A series of in vitro cell assays were used to test the efficacy of these formulations. The small size and functional versatility of these nanoparticles, combined with their ability to incorporate various drugs, indicates that lapatinib/PTX nanocolloids may have in vivo therapeutic applications.

Graphical Abstract 

I) A principal scheme of LbL nanoparticles formation from insolubile drugs. II) The citotoxic potential of Lapatinib / Paclitaxel polyelectrolyte nanocapsules was evaluated in a chemoresistant ovarian cancer cell line. After administration, drugs-loaded nanoparticles exerted a significant increase in the therapeutic activity compared with free paclitaxel.

Key words: Ovarian cancer, Lapatinib, Paclitaxel, Nanocapsules, Sonication-assisted Layer-by-Layer

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 No conflict of interest was reported by the authors of this article.

 This work was funded by the Italian Ministry of University and Research (MIUR) through the FIRB project no. RBLA03ER38, “Con il contributo del Ministero degli Affari Esteri (MAE), Direzione Generale per la promozione e la Cooperazione Sociale ” (Italy –USA Large Scale Bilateral Project “Nano-trasportatori per la terapia del cancro”). This work was also supported by the PS105 ARTI strategic project “Development and realization of bio-chip for molecular diagnostic and categorization of human pathogenic viruses (HPV, HCV)” of Apulia Region and by a contribution of “ANGELA SERRA” Foundation For Cancer Research, Parabita (Lecce, Italy). No support came from any commercial association.

PII: S1549-9634(11)00522-3

doi:10.1016/j.nano.2011.10.014

« BackNanomedicine: Nanotechnology, Biology and Medicine

Article Tools

* Image Usage & Resolution